Publications

  1. Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013 Jun; 129(3):478-85. Epub 2013 Mar 25. 2313151
    View PubMed
  2. Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):315-9. Epub 2012 Feb 01. 2150279
    View PubMed
  3. Viswanathan AN, Creutzberg CL, Craighead P, McCormack M, Toita T, Narayan K, Reed N, Long H, Kim HJ, Marth C, Lindegaard JC, Cerrotta A, Small W Jr, Trimble E. International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):250-5. Epub 2010 Dec 22. 2216630
    View PubMed
  4. Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012 Jan; 38(1):340-4. Epub 2011 Dec 05. 2209930
    View PubMed
  5. Sandhu NP, Long HJ, Johnson KJ, Degnim AC. An unusual presentation of breast cancer in a very young woman. BMJ Case Rep. 2011; 2011. Epub 2011 Mar 15. 2252639
    View PubMed
  6. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA. From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol. 2010 Sep; 21(9):1772-8. Epub 2010 Feb 05. 2112357
    View PubMed
  7. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010 May; 117(2):248-54. Epub 2010 Feb 26. 1997947
    View PubMed
  8. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45(3):490-7. Epub 2009 Aug 03. 1956969
    View PubMed
  9. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26. 1983174
    View PubMed
  10. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Jan; 116(1):44-9. Epub 2009 Oct 22. 1885953
    View PubMed
  11. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar; 112(3):543-52. Epub 2008 Dec 23. 1934923
    View PubMed
  12. Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B. Phase I trial of intraperitoneal administration of an engineered attenuated strain of measles virus, genetically modified to express carcinoembryonic antigen (CEA) in patients with recurrent ovarian cancer. [forthcoming] J Clin Oncol. 2009; JCO/2407. 1947884
  13. Plaxe SC, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol. 2008 Nov; 199(5):539.e1-6. Epub 2008 Jun 20. 1955322
    View PubMed
  14. Long HJ 3rd, Laack NN, Gostout BS. Prevention, diagnosis, and treatment of cervical cancer. Mayo Clin Proc. 2007 Dec; 82(12):1566-74. 1859042
    View PubMed
  15. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007 Jul 10; 25(20):2966-74. 1830739
    View PubMed
  16. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol. 2007 Jan; 104(1):212-6. Epub 2006 Oct 04. 1804867
    View PubMed
  17. Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar; 100(3):537-43. Epub 2005 Oct 10. 1968802
    View PubMed
  18. Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM Jr, Kardinal CG, Wos EJ. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecol Oncol. 2006 Mar; 100(3):501-5. Epub 2005 Sep 26. 1968721
    View PubMed
  19. Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, Koelliker S, Siegelman ES, Brown JJ, McGhee RB, Iyer R, Vitellas KM, Snyder B, Long HJ, Fiorica JV, Mitchell DG. Role of imaging in pretreatment evaluation of early invasive cervical cancer: Results of the Intergroup Study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005 Dec 20; 23(36):9329-37. 1743597
    View PubMed
  20. Long HJ 3rd, Blessing JA, Sorosky J. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Nov; 99(2):339-42. Epub 2005 Jul 26. 1733858
    View PubMed
  21. Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ, Fiorica JV, Gatsonis C. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the united states: Results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol. 2005 Oct 20; 23(30):7454-9. 1733751
    View PubMed
  22. Monk BJ, Huang HQ, Cella D, Long HJ. Quality of life outcomes from a Randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol. 2005 Jul 20; 23(21):4617-25. 1729848
    View PubMed
  23. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20; 23(21):4626-33. Epub 2005 May 23. 1967432
    View PubMed
  24. Mariani A, Dowdy SC, Keeney GL, Long HJ, Lesnick TG, Podratz KC. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol. 2004 Oct; 95(1):120-6. 1667521
    View PubMed
  25. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 2004 Jan 15; 100(2):321-6. 1519970
    View PubMed
  26. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, Hurteau J, Alberts DS. Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal P-32 or intravenous cyclophosphamide and cisplatin - A gynecologic oncology group study. J Clin Oncol. 2003 Dec 1; 21(23):4350-5. 1429095
    View PubMed
  27. Long HJ 3rd. Current research directions for locally advanced cervix cancer. Curr Oncol Rep. 2003 Nov; 5(6):468-72. 1646983
    View PubMed
  28. Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003 Aug 1; 21(15):2843-8. Epub 2003 Jun 13. 1405684
    View PubMed
  29. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal radioactive phosphorus (P-32) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003 Aug 1; 21(15):2849-55. 1405685
    View PubMed
  30. Varia M, Stehman F, Bundy B, Benda J, Clarke-Pearson D, Alvarez R, Long H Intraperitoneal Radioactive Phosphorus (32P) Versus Observation Following Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group J Clin Oncol. 2003; 21:2849-2855. 2010294
    View PubMed
  31. Long HJ 3rd, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002 Dec; 25(6):547-51. 1317787
    View PubMed
  32. Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ. Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer. Am J Obstet Gynecol. 2002 Jun; 186(6):1167-73. 1316065
    View PubMed
  33. Peethambaram PP, Long HJ. Second-line and subsequent therapy for ovarian carcinoma. Curr Oncol Rep. 2002 Mar; 4(2):159-64. 1315179
    View PubMed
  34. Edmonson JH, Suman VJ, Dalton RJ, Bro WC, Gallenberg MM, Long HJ, Levitt R, Hatfield AK, Krook JE, Mailliard JA, Gerstner JB, North Central Cancer Treatment Group. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study. Cancer Invest. 2001; 19(6):597-602. 1979972
    View PubMed
  35. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun; 17(6):1884-90. 117151
    View PubMed
  36. Edmonson JH, Long HJ, Kvols LK, Mann BS, Grill JP. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol. 1997 Jul; 8(7):637-41. 1015606
    View PubMed
  37. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, Teneriello M, Averette HA, Sevin BU. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996 Apr; 61(1):3-10. 1025779
    View PubMed
  38. Long HJ 3rd, Langdon RM Jr, Cha SS, Veeder MH, Pfeifle DM, Krook JE, Ebbert LP, Tschetter LK, Roshon SG. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1995 Aug; 58(2):240-3. 93534
    View PubMed
  39. Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol. 1995 May; 57(2):235-9. 1022455
    View PubMed
  40. Ingle JN, Kuross SA, Mailliard JA, Loprinzi CL, Jung SH, Nelimark RA, Krook JE, Long HJ. Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy. Cancer. 1994 Sep 15; 74(6):1733-8. 1033830
    View PubMed
  41. Long HJ 3rd, Nelimark RA, Su JQ, Garneau SC, Levitt R, Goldberg RM, Poon MA, Kugler JW. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol. 1994 Aug; 54(2):180-3. 1032184
    View PubMed
  42. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc. 1994 Apr; 69(4):341-5. 1032101
    View PubMed
  43. Lee TC, Hook CC, Long HJ. Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy. Mayo Clin Proc. 1994 Jan; 69(1):80-2. 86964
    View PubMed
  44. Long H, Nelimark R, Su J, Garneau S, Levitt R, Goldberg R, Poon M, Kugler J Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma Gynecologic Oncology. 1994; 54:180-183. 2003107
    View PubMed
  45. Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long HJ. Localized ovarian cancer in the elderly. Cancer. 1993 Jan 15; 71:601-605. 1029209
    View PubMed
  46. Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer. 1992 Nov 15; 70(10):2529-39. 1040387
    View PubMed
  47. Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, Fujii S, Long HJ III, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia. 1992 Jul-Dec; 19(3-4):131-49. 1295659
    View PubMed
  48. Halberg E, Long HJ III, Cornelissen G, Blank MA, Elg S, Touitou Y, Bakken E, Delmore P, Haus E, Sackett-Lundeen L, Prem K, Halberg F. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125. Chronobiologia. 1992 Jan-Mar; 19(1-2):17-42. 1295658
    View PubMed
  49. Long HJ. Medicine's battle with cancer: screening still key element of armamentarium. Minn Med. 1992; 75:17-9. 1295661
    View PubMed
  50. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, Levitt R, Pfeifle DM. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: an updated analysis. Pages 169-71 in:. The Yearbook of Oncology RC Young RC, Editor St , 1992 1992; Louis:Mosby. 1295572
  51. Hauge MD, Long HJ, Hartmann LC, Edmonson JH, Webb MJ, Su J. Phase II trial intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest New Drugs. 1992; 10:299-301. 1039935
    View PubMed
  52. Long HJ, Wieand HS, Foley JF, Niedringhaus RD, Laurie JA, Morton RF, Goldberg RM, Mailliard JA, Malkasian GD, Edmonson JH. Phase II evaluation of menogaril in patients with advanced cervical carcinoma: a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Invest New Drugs. 1991 Nov; 9:349-51. 1037708
    View PubMed
  53. Long HJ 3rd, Laurie JA, Wieand HS, Edmonson JH, Levitt R, Krook JE, Abu-Ghazaleh S. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. Cancer. 1991 Aug 15; 68(4):730-2. 1037512
    View PubMed
  54. Long HJ, Hauge MD, Therneau TM, Buckner JC, Frytak S, Hahn RG. Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs. 1991 Aug; 9(3):261-2. 142272
    View PubMed
  55. Ahmann DL, Schaid DJ, Ingle JN, Bisel HF, Schutt AJ, Buckner JC, Long HJ, Rubin J. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol. 1991 Jun; 14(3):179-83. 76692
    View PubMed
  56. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991 Feb 15; 67(4):886-91. 1313669
    View PubMed
  57. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, Foley JF, Loprinzi CL, Dalton RJ. A double-blind trial of tamoxifen plus prednisone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer. 1991; 68:34-39. 78445
    View PubMed
  58. Cornelissen G, Halberg E, Long HJ III, Prem K, Bakken E, Touitou Y, Elg S, Haus E, Halberg F. Toward a chronotherapy of ovarian cancer with taxol. Part I: basic background. Chronobiologia. 1991; 18:153-66. 1295653
    View PubMed
  59. Elg S, Halberg E, Ramakrishnan S, Cornelissen G, Haus E, Nicolau G, Carson L, Twiggs L, Long HJ III, Halberg F. Marker rhythmometry with M-CSF. Chronobiologia. 1991; 18:141-52. 1295650
    View PubMed
  60. Creagan ET, Long HJ, Ahmann DL, Schaid DJ. Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma. Am J Clin Oncol. 1990 Jun; 13(3):218-20. 72653
    View PubMed
  61. Ingle JN, Krook JE, Schaid DJ, Everson LK, Mailliard JA, Long HJ, McCormack GW. Evaluation of trilostane plus hydrocortisone in women with metastatic breast cancer and prior hormonal therapy exposure. Am J Clin Oncol. 1990 Apr; 13(2):93-7. 74989
    View PubMed
  62. Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gerstner JB, Pfeifle DM, Marschke RF, Long HJ, McCormack GW, Foley JF. Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. Am J Clin Oncol. 1989 Dec; 12(6):474-80. 71282
    View PubMed
  63. De Fusco PA, Gaffey TA, Malkasian GD, Long HJ, Cha SS. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol. 1989 Oct; 35(1):8-14. 70021
    View PubMed
  64. Creagan ET, Frytak S, Long HJ, Kvols LK. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease. Cancer. 1989 Sep 1; 64(5):1034-7. 1045468
    View PubMed
  65. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL, Schaid DJ. Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst. 1989 Jun 7; 81(11):863-6. 69114
    View PubMed
  66. Long HJ, Schaid DJ, Schutt AJ, Ingle JN, Loprinzi CL, Edmonson JH. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy. Am J Clin Oncol. 1988 Oct; 11(5):524-7. 66525
    View PubMed
  67. Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol. 1988 Sep; 31(1):9-24. 1042904
    View PubMed
  68. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Long HJ, Gerstner JG, Windschitl HE, et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol. 1988 May; 6(5):825-31. 2106856
    View PubMed
  69. Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmonson JH, Buckner JC. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst. 1988 Apr 20; 80(4):276-8. 1043645
    View PubMed
  70. Creagan ET, Long HJ, Frytak S, Moertel CG. Recombinant leukocyte A interferon wiwh doxorubicin: phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer. 1988; 61:19-22. 1295647
    View PubMed
  71. Luiken GA, Marsh WL Jr, Heath VC, Long HJ, Weatherly TL, Seal GM. Hematologic evaluation of employees with leukopenia: Naval Weapons Center, China Lake, California. Am J Clin Pathol. 1988; 90:679-84. 1295648
    View PubMed
  72. Long H, Pfeifle D, Wieand H, Krook J, Edmonson J, Buckner J Phase II evaluation of carboplatin in advanced endometrial carcinoma J Natl Cancer Inst. 1988; 80:276-278. 2003021
    View PubMed
  73. Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep. 1987 Sep; 71(9):843-4. 1055505
    View PubMed
  74. Edmonson JH, Long HJ, Frytak S, Smithson WA, Itri LM. Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treat Rep. 1987 Jul-Aug; 71(7-8):747-8. 1054707
    View PubMed
  75. Long HJ, Powis G, Schutt AJ, Moertel CG. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. Cancer Treat Rep. 1987 Jun; 71(6):593-8. 1054584
    View PubMed
  76. Creagan ET, Chang M, Long HJ, Rubin J. Phase II clinical trial of the combination VP-16, bleomycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive squamous cell carcinoma. Head & Neck Surgery. 1987 Mar-Apr; 9(4):223-6. 1054188
    View PubMed
  77. Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer. 1987 Feb 1; 59(3 Suppl):638-46. 1054605
    View PubMed
  78. Edmonson JH, Long HJ, Creagan ET, Frytak S, Sherwin SA, Chang MN. Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomas. Cancer Treat Rep. 1987 Feb; 71(2):211-3. 1054123
    View PubMed
  79. Edmonson JH, McCormack GW, Krook JE, Long HJ, Jefferies JA, Richardson RL. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma. Cancer Treat Rep. 1987 Feb; 71(2):199-200. 1054131
    View PubMed
  80. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol. 1987 Feb; 10(1):82-5. 61253
    View PubMed
  81. Creagan ET, Long HJ, Frytak S, Moertel CG. Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer. 1987 Jan 1; 61:19-22. 1055851
  82. Creagan ET, Ahmann DL, Frytak S, Long HJ, Itri LM. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer. 1986 Dec 15; 58(12):2576-8. 1052841
    View PubMed
  83. Ingle JN, Long HJ, Schutt AJ, Chang MN. Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer. Am J Clin Oncol. 1986 Oct; 9(5):379-81. 1053115
    View PubMed
  84. Edmonson JH, Krook JE, Hilton JF, Long HJ 3rd, Cullinan SA, Everson LK, Malkasian GD. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment. Cancer Treat Rep. 1986 Aug; 70(8):1019-20. 1052006
    View PubMed
  85. Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep. 1986 May; 70(5):619-24. 1052196
    View PubMed
  86. Creagan ET, Kovach JS, Long HJ, Richardson RL. Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol. 1986 Mar; 4(3):408-13. 1051501
    View PubMed
  87. Creagan ET, Chang M, Long HJ, Rubin J. A phase II clinical trial of the combination mitomycin C, adriamycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive cancer. Head & Neck Surgery. 1986 Jan-Feb; 8(3):153-8. 1051299
    View PubMed
  88. Creagan ET, Schutt AJ, Long HJ, Green SJ. Phase II study of the combination DTIC, BCNU, Actinomycin D, and vincristine in disseminated malignant melanoma. Med Pediatri Oncol. 1986; 14:86-7. 1290396
  89. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol. 1986;4:958-64. 1053137
    View PubMed
  90. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, Itri LM. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Onc. 1985 Jul; 3:977-81. 1289958
  91. Creagan ET, Long HJ, Kvols LK, Edmonson JH, O'Fallon JR. Phase II trial of diaziquone in advanced upper aerodigestive cancer. Cancer Treat Rep. 1985 Jan; 69(1):141. 54144
    View PubMed
  92. Edmonson JH, Long HJ, Richardson RL, Creagan ET, Green SJ. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemotherapy & Pharmacology. 1985; 15(2):181-2. 1050123
    View PubMed
  93. Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ, Dziewanowski ZE. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer. 1984 Dec 15; 54(12):2844-9. 1120174
    View PubMed
  94. Creagan ET, Long HJ, Ahmann DL, Green SJ. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am J Clin Oncol. 1984 Oct; 7(5):543-4. 1119667
    View PubMed
  95. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, O'Fallon JR, Itri LM. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol. 1984 Sep; 2(9):1002-5. 52310
    View PubMed
  96. Long HJ, Diamond SS, Rafflo CP, Burningham RA. Dose-response relationships of chronic adriamycin toxicity in rabbits. Eur J Cancer Clin Oncol. 1984; 20:129-35. 1295645
    View PubMed
  97. Marsh WL, Stevenson DR, Long HJ. Primary leptomeningeal presentation of T-cell lymphoma: report of a patient and review of the literature. Cancer. 1983; 51:1125-31. 1295642
    View PubMed
  98. Long HJ, Diamond SS, Burningham RA, Rafflo CP. Systolic time interval recordings as a measure of cardiac function in the healthy rabbit: reference values. Am J Vet Res. 1982; 3:1497-9. 1295640
  99. Long HJ, Aplastic anemia. A rare complication of disseminated BCG infection: case report. Milit Med. 1982; 47:1067-70. 1295641
  100. Dennish GW 3rd, Long HJ 3rd, Pepine CJ. Aortocoronary sinus anastomosis: a postoperative follow-up 24 years later. Am Heart J. 1979 May; 97(5):631-4. 1108077
    View PubMed
  101. Long HJ. Systolic time intervals: an effective measure of cardiac function in anthracycline-induced cardiomyopathy of rabbits. Cancer Treat Rep. 1978 Jun; 62(6):911-4. 1106144
    View PubMed
  102. Dainer PM, Long HJ. Laetril and chronic myelogenous leukemia. N Engl J Med. 1978; 297:221-2. 1295677
  103. Long HJ, Burningham RA. Selected medical oncologic emergencies. Navy Med. 1975 Jun; 65:14-20. 1101131
  104. Long HJ, Burningham RA. Therapy for metastatic breast cancer: the state of the art. Navy Med. 1974 Nov; 64:19-22. 1099562